Abstract
Alzheimer’s Disease (AD) is the major cause of senile dementia, flawing out 10% of 65 years old population and 50% of 85 years old, globally. The major physiopathology of AD is the deposition of extracellular neuritic plaques in memory related areas of the brain. These plaques are composed of the β-amyloid peptide resulting from the amyloidogenic pathway, that starts with the β-secretase enzyme. BACE-1 (β-secretase 1) is considered one of the most promising treatments of the disease. In this work, different molecular modeling and drug design techniques were used to design novel inhibitors of BACE-1, starting from structures available in the Protein Data Bank. The results obtained from virtual screening of compound libraries lead to 28 promising compounds, which were then evaluated by toxicity prediction, pharmacokinetic properties and analysis of the binding modes in the catalytic site, resulting in 10 compounds with high theoretical inhibition potential.
Keywords: BACE-1, Alzheimer, virtual screening
Current Bioactive Compounds
Title:Structure and Ligand Based Rational Drug Design for Bace-1 Inhibitors
Volume: 9 Issue: 1
Author(s): E. P. Semighini, Carlton A. Taft and C. H. T. P. Silva
Affiliation:
Keywords: BACE-1, Alzheimer, virtual screening
Abstract: Alzheimer’s Disease (AD) is the major cause of senile dementia, flawing out 10% of 65 years old population and 50% of 85 years old, globally. The major physiopathology of AD is the deposition of extracellular neuritic plaques in memory related areas of the brain. These plaques are composed of the β-amyloid peptide resulting from the amyloidogenic pathway, that starts with the β-secretase enzyme. BACE-1 (β-secretase 1) is considered one of the most promising treatments of the disease. In this work, different molecular modeling and drug design techniques were used to design novel inhibitors of BACE-1, starting from structures available in the Protein Data Bank. The results obtained from virtual screening of compound libraries lead to 28 promising compounds, which were then evaluated by toxicity prediction, pharmacokinetic properties and analysis of the binding modes in the catalytic site, resulting in 10 compounds with high theoretical inhibition potential.
Export Options
About this article
Cite this article as:
Semighini E. P., A. Taft Carlton and Silva C. H. T. P., Structure and Ligand Based Rational Drug Design for Bace-1 Inhibitors, Current Bioactive Compounds 2013; 9 (1) . https://dx.doi.org/10.2174/1573407211309010003
DOI https://dx.doi.org/10.2174/1573407211309010003 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dimethyl-Carbamic Acid 2,3-Bis-Dimethylcarbamoyloxy-6-(4-Ethyl-Piperazine- 1-Carbonyl)-Phenyl Ester: A Novel Multi-Target Therapeutic Approach to Neuroprotection
Medicinal Chemistry Interrelationships Among Gut Microbiota and Host: Paradigms, Role in Neurodegenerative Diseases and Future Prospects
CNS & Neurological Disorders - Drug Targets Recent Advancements in Nanodiamond Mediated Brain Targeted Drug Delivery and Bioimaging of Brain Ailments: A Holistic Review
Pharmaceutical Nanotechnology The Role of Disproportionality Analysis of Pharmacovigilance Databases in Safety Regulatory Actions: a Systematic Review
Current Drug Safety Conformationally Controlled Mechanistic Aspects of BACE 1 Inhibitors
Central Nervous System Agents in Medicinal Chemistry Intracerebrally Applied Botulinum Neurotoxin in Experimental Neuroscience
Current Pharmaceutical Biotechnology Mechanisms of Action of Non-Steroidal Anti-Inflammatory Drugs for the Prevention of Alzheimers Disease
CNS & Neurological Disorders - Drug Targets The Valsalva Maneuver and Alzheimers Disease: Is there a link?
Current Alzheimer Research Targeting Neurotrophin Receptors in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Pharmacological Effects of Turmeric on Learning, Memory and Expression of Muscarinic Receptor Genes (M1, M3 and M5) in Stress-induced Mouse Model
Current Drug Targets Drainage of Cerebral Abscesses Prior to Valve Replacement in Stable Patients with Acute Left-Sided Infective Endocarditis
CNS & Neurological Disorders - Drug Targets GABAA/Bz Receptor Subtypes as Targets for Selective Drugs
Current Medicinal Chemistry Is Formaldehyde the Missing Link in AD Pathology? The Differential Aggregation of Amyloid-Beta with APOE Isoforms In Vitro
Current Alzheimer Research Transcranial Magnetic Stimulation on Rodent Models
CNS & Neurological Disorders - Drug Targets Hypersensitivity Reactions to Complementary and Alternative Medicine Products
Current Pharmaceutical Design A Hydrazide Linker Strategy for Heterobivalent Compounds as Ortho- and Allosteric Ligands of Acetylcholine-Binding Proteins
Current Topics in Medicinal Chemistry Therapeutic Approaches to Modulating Glutathione Levels as a Pharmacological Strategy in Alzheimer`s Disease
Current Alzheimer Research Tetracyclic Triterpenoids in Herbal Medicines and their Activities in Diabetes and its Complications
Current Topics in Medicinal Chemistry Natural Non-Trasgenic Animal Models for Research in Alzheimers Disease
Current Alzheimer Research Evidence that Ingested Aluminum Additives Contained in Processed Foods and Alum-Treated Drinking Water are a Major Risk Factor for Alzheimers Disease
Current Inorganic Chemistry (Discontinued)